SRI International will provide preclinical treatment development support for the National Cancer Institute’s Prevent Cancer Drug Development Program under a potential $9 million contract.
NCI’s Prevent initiative aims to advance the development of biomarkers and drug candidates designed to prevent cancer and transition them from preclinical phase to clinical trials, SRI said Monday.
Toufan Parman, director of general toxicology at SRI’s biosciences organization and principal investigator for the contract, said the company has provided preclinical pharmacology and toxicology support services to NCI for more than two decades.
The contract covers analytical instrumentation, laboratory data collection, testing and scientific support to assess potential treatment candidates against cancer.
SRI will also develop and file an investigational new drug application with the Food and Drug Administration under the contract.